Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.
← catalyst calendarSponsored by Palisade Bio (industry) · PALI — their whole pipeline →. With Altasciences Company Inc..
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
89actual
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-05 | actual | When the study began enrolling |
| Primary completion | 2025-07-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-07 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ulcerative Colitis (UC)
- Healthy Volunteer
Interventions
- Drug: PALI-2108 — also filed as PALI-2108 active drug
- Drug: PALI-2108 Placebo
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events (TEAE) or abnormal clinical laboratory measure, electrocardiogram (ECG), or vital sign. [ Safety and Tolerability ]
measured SAD and FE Phase: [ Day 1 to Day 7 ], MAD and UC Phase: [ Days 1 to Day 28 ]
Permalink · PALI's whole pipeline · Catalyst calendar · Every registered study · What changed